Information:
Fel:
ID
34226
Beskrivning
The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion; ODM derived from: https://clinicaltrials.gov/show/NCT01655524
Länk
https://clinicaltrials.gov/show/NCT01655524
Nyckelord
Versioner (1)
- 2019-01-15 2019-01-15 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
15 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Coronary Artery Disease NCT01655524
Eligibility Coronary Artery Disease NCT01655524
- StudyEvent: Eligibility
Similar models
Eligibility Coronary Artery Disease NCT01655524
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
patients who have had a qualifying regadenoson stress myocardial perfusion imaging (regadenoson nuclear stress test).
boolean
ID.2
Item
inability to provide an informed consent
boolean
ID.3
Item
known allergic reaction to aminophylline or regadenoson
boolean
ID.4
Item
systolic blood pressure < 90 mmhg
boolean
ID.5
Item
unstable abnormal heart rhythm
boolean
ID.6
Item
pulmonary edema
boolean
ID.7
Item
acute coronary symptoms, myocardial infarction within 48 hours
boolean
ID.8
Item
active dipyridamole, aminophylline or theophylline use
boolean
ID.9
Item
pregnancy
boolean
ID.10
Item
any contraindication to aminophylline according to the drug's package insert: uncontrolled seizure disorder, sepsis with multi-organ failure and liver impairment
boolean